# Pai Zhu

> Pai Zhu is a Series B investor at EFung Capital backing Biotechnology and Genetics. See 6 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [EFung Capital](https://shizune.co/investors/profile/efung-capital)
- Total investments: 6
- Last investment: Jun 2024
- Lead investor: 83%
- Last updated: Aug 2026

Pai Zhu is a Series B investor at EFung Capital focused on Biotechnology and Genetics. Zhu Pai is the managing partner of Yifeng Capital.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 3 | 50% |
| Genetics | 2 | 33% |
| Clinical Trials | 2 | 33% |
| Biopharma | 1 | 17% |
| Health Care | 1 | 17% |

9 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 2 | 33% |
| Seed | 1 | 17% |
| Series A | 1 | 17% |
| Series C | 1 | 17% |
| Venture - Series Unknown | 1 | 17% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| China | 5 | 83% |
| Japan | 1 | 17% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| CATUG Biotechnology | CATUG is focused on the development and application of new biomedical technologies. It provides one-stop CDMO services for the entire industry chain from quality research and clinical application to industrialization. It has R&D centers and industrialization bases in Suzhou and Wuhan. | $13.8M | Venture - Series Unknown | Jun 12, 2024 |  |
| Century Kangtai | Century Kangtai is a Class III medical device manufacturer that combines production, research and development, and sales. Century Kangtai is a collagen material developer and ophthalmic clinical trial company. Its primary business is the research and development, production, and marketing of ocular implant devices, as well as the provision ofafter-sales services to consumers. It has computer numerical control air suspension and uses laser navigation technology and laser interference. Products that use measurement technology include integrated posterior chamber intraocular lenses, ocular fixation rings, and collagen sponges. |  | Series B | Sep 20, 2023 |  |
| Lingyi Biology | Lingyi Bio is a rare disease animal model functional verification platform and gene therapy developer. | $14.5M | Series A | May 06, 2023 |  |
| Maijing Gene | Maijing Gene is a gene detection technology company that specializes in R&D, production, and sales of molecular diagnostic products. It is also committed to promoting the application of second-generation high-throughput sequencing technology in the field of precision medicine.Maijing Gene was established in 2015 and is based in Guangzhou,China. |  | Series C | Dec 29, 2022 |  |
| Beimei Pharmaceutical | Beimei Pharmaceutical is a biotech company focusing on the research and deveopment of children's prescription drugs. | $15.7M | Series B | Apr 02, 2022 |  |
| West Lake Omi | Westlake Omi combines proteomic big data with artificial intelligence, mass spectrometry-based biological sample digitization technology. |  | Seed | Jan 13, 2022 |  |

6 of 6 investments shown.

## Co-investors
- [Gaorong Capital](https://shizune.co/investors/profile/banyan-capital) — VC Fund, 1 deal together
- [Beijing Huafang Investment](https://shizune.co/investors/profile/beijing-huafang-investment) — VC Fund, 1 deal together
- [Dongguan Songshan Lake Science City Venture Capital](https://shizune.co/investors/profile/dongguan-songshan-lake-science-city-venture-capital) — VC Fund, 1 deal together
- [EFung Capital](https://shizune.co/investors/profile/efung-capital) — VC Fund, 1 deal together
- [Hillhouse Investment](https://shizune.co/investors/profile/hillhouse-capital) — VC Fund, 1 deal together
- [Hillhouse Investment](https://shizune.co/investors/profile/hillhouse-investment) — VC Fund, 1 deal together

## About EFung Capital

VC Fund · Shenzhen, China

Shenzhen EFUNG Investment Management Enterprise L. P. is one of China's earliest institutions investing in professional biomedical industries. Their strong research team and great investment returns made us won 'The Most Pioneering VC Institution” 'The Most Dynamic Pharmaceutical VC Institution in China' and 'The Top Ten VCInstitutions in Shenzhen'. With this influence, EFUNG has drawn a lot of attention from the medical and life science industry. And it is interviewed by Nature, which is the most authoritative science magazine in the world. Over a decade of years, they have been focusing on the medical and health industry, especially the VC and PE investment business of novel drugs and high-end medical devices. The mission of EFUNG is to drive the industrialization of medical researches by capital and to gain rich returns to investors. EFUNG has deeply screened and invested in more than 20 domestic and international premium enterprises, such as Chipscreen Biosciences, Frontier Biotechnologies, Ascentage Pharma, Lifotronic, Aridis Pharmaceuticals, and Centrexion.

4 contacts available at EFung Capital.

| Name | Title | Profile |
| --- | --- | --- |
| Jinqiao Zhu | Founder | https://shizune.co/investors/profile/jinqiao-zhu |
| Luo Fayong | Managing Director | https://shizune.co/investors/profile/luo-fayong |
| Pai Zhu | Managing Partner | https://shizune.co/investors/profile/pai-zhu |
| Yu Wang | Chief Scientist | https://shizune.co/investors/profile/yu-wang-87d2 |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Pai Zhu invest in?

Pai Zhu invests primarily in Biotechnology, Genetics and Clinical Trials startups, most often at Series B and Seed stage. Most of the 6 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Pai Zhu last invest?

The most recent investment recorded for Pai Zhu closed in Jun 2024. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co